Home
About
Overview
Management Team
Board of Directors
Medical Advisory Board
Product Pipeline
Overview
Nyxol
APX3330
APX2009
Posters and Publications
Clinical Trials
Overview
VEGA-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia
Enrolling
ZETA-1: Diabetic Retinopathy Phase 2 Clinical Trial for APX3330
Last Patient Last Visit Completed
MIRA-4: Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects
Completed
MIRA-3
Completed
MIRA-2: Reversal of Mydriasis Phase 3 Clinical Trial for Nyxol
Completed
LYNX-1: Dim Light Vision Disturbance Phase 3 Clinical Trial for Nyxol
Completed
VEGA-1: Presbyopia Phase 2 Clinical Trial for Nyxol with Low-Dose Pilocarpine
Completed
Partnerships
News & Media
Press Releases
Presentations
Events
Ocuphire in the News
Investors
Overview
News / Events
Company Information
Financial Information
Stock Data
SEC Filings
Corporate Governance
Contact
Careers
Clinical Trials
Clinical Trials
Clinical Trials
Overview
VEGA-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia
ZETA-1: Diabetic Retinopathy Phase 2 Clinical Trial for APX3330
MIRA-4: Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects
MIRA-3
MIRA-2: Reversal of Mydriasis Phase 3 Clinical Trial for Nyxol
LYNX-1: Dim Light Vision Disturbance Phase 3 Clinical Trial for Nyxol
VEGA-1: Presbyopia Phase 2 Clinical Trial for Nyxol with Low-Dose Pilocarpine
Current Trials
Enrolling
Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia
VEGA-2: Pivotal Phase 3 Trial of Nyxol® in Presbyopia
VEGA-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia:
View Clinical Trial
Last Patient Last Visit Completed
Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy
ZETA-1: Diabetic Retinopathy Phase 2 Clinical Trial for APX3330
ZETA-1: Diabetic Retinopathy Phase 2 Clinical Trial for APX3330:
View Clinical Trial
Completed Trials
Completed
Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis
Reversal of Mydriasis Phase 2 Clinical Trial with Nyxol
Reversal of Mydriasis Phase 2 Clinical Trial with Nyxol:
View Clinical Trial
Completed
Safety and Efficacy of Ophthalmic Phentolamine Mesylate in Glaucoma
Phase 2 Clinical Trial of Nyxol in Elderly Subjects with Glaucoma
Phase 2 Clinical Trial of Nyxol in Elderly Subjects with Glaucoma:
View Clinical Trial
Completed
Single Dose Study of Phentolamine Mesylate Eye Drops in Patients With Severe Night Vision Disturbances
Severe Night Vision Disturbance Single-Dose Phase 2 Clinical Trial with Nyxol
Severe Night Vision Disturbance Single-Dose Phase 2 Clinical Trial with Nyxol:
View Clinical Trial
Completed
The Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision Disturbances
Night Vision Complaints Multiple-Dose Phase 2 Clinical Trial with Nyxol
Night Vision Complaints Clinical Trial:
View Clinical Trial
Completed
A Study of APX3330 in Patients With Advanced Solid Tumors
APX3330 Cancer Phase 1 Clinical Trial
APX3330 Cancer Phase 1 Clinical Trial:
View Clinical Trial
Completed
Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects
MIRA-4: Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects
MIRA-4: Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects:
View Clinical Trial
Completed
Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)
MIRA-3: A Phase 3 Clinical Trial Evaluating the Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)
MIRA-3:
View Clinical Trial
Completed
Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis
MIRA-2: Reversal of Mydriasis Phase 3 Clinical Trial for Nyxol
MIRA-2: Reversal of Mydriasis Phase 3 Clinical Trial for Nyxol:
View Clinical Trial
Completed
Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances
LYNX-1: Dim Light Vision Disturbance Phase 3 Clinical Trial for Nyxol
LYNX-1: Dim Light Vision Disturbance Phase 3 Clinical Trial for Nyxol:
View Clinical Trial
Completed
Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With Presbyopia
VEGA-1: Presbyopia Phase 2 Clinical Trial for Nyxol with Low-Dose Pilocarpine
VEGA-1: Presbyopia Phase 2 Clinical Trial for Nyxol with Low-Dose Pilocarpine:
View Clinical Trial